RxDoctor Payments DataLook up a doctor →

Timothy Grube, DO

Obstetrics & Gynecology · Frackville, PANPI 1194720870

Payments from drug & device makers

$290,525in general payments, 2019–2025

Across 443 payments — averaging $655.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$203K
  • AbbVie$83K
  • Medtronic$2K
  • Astellas Pharma US Inc$482
  • Axonics, Inc.$295
  • Sumitomo Pharma America, Inc.$269
  • plus $2K from 25 others

What the payments were for

  • Speaking & faculty fees$47,40018%
  • Travel & lodging$5,1662%
  • Food & beverage$15,6456%
  • Education$192,16474%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$290,525 in reported general payments places this provider in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.

See all obstetrics & gynecology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$99,104
Medicare patients
167
Services billed
2,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron40$36,309
GemtesaVibegron26$22,566
ProliaDenosumab12$21,558
PremarinEstrogens, Conjugated21$7,450
PremproEstrogen,con/M-Progest Acet17$6,554
Estradiol45$5,248
ValacyclovirValacyclovir Hcl26$1,588
ProgesteroneProgesterone, Micronized21$1,451
Clobetasol Propionate13$401
Solifenacin Succinate27$388
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$205
Ibuprofen27$181
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$167
Bethanechol Chloride18$167
Oxybutynin Chloride11$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$482$36,30940 claims
Sumitomo Pharma America, Inc.Gemtesa$269$22,56626 claims
AmgenProlia$77$21,55812 claims
PfizerPremarin, Prempro$237$14,00538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.

Other obstetrics & gynecology in Frackville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →